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duration of all LHRH agonist use was 26.3 weeks and 33.2
weeks in younger and older patients, respectively (P  0.05).
LHRH agonists were used for 24 weeks and 48 weeks in
56.4% and 17.6% of younger and in 43.3% and 28.3% of
older patients. Average duration of anti-androgen use for
CAB patients was 34.7 and 39.8 weeks in younger (n  80)
and older patients (n  117, P  ns). Anti-androgens were
used for 24 weeks and 48 weeks in 43.8% and 31.3% of
younger and in 40.2% and 36.8% of older patients.
CONCLUSIONS: The duration of LHRH agonist use by
prostate cancer patients varies by age. Large proportions
of patients in both age groups use CAB for 24 weeks,
suggesting use to protect against testosterone surge. Ad-
ditional research is required to verify these results.
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OBJECTIVES: To compare the efficiency (the evaluation
of efficacy in relation to costs) of three first-line treatment
options for advanced non-small-cell lung cancer (stage IIIB
and IV) used in the ECOG study: docetaxel/cisplatin (75/
75 mg/m2/day; 1 hour IV infusion of docetaxel); paclitaxel/
cisplatin (175/75 mg/m2/day; 3 or 24 hour IV infusion of
paclitaxel), and paclitaxel/carboplatin (175/400 or 225/
400 mg/m2/day; 3 hour IV infusion of paclitaxel).
METHODS: The results of the ECOG 1594 phase III clin-
ical trial demonstrated equivalent efficacy (survival, objec-
tive response) between the treatment options. To differen-
tiate between the treatment options, we performed a cost-
minimization analysis, using a pharmacoeconomic model.
RESULTS: The average estimated treatment cost per patient
(median, four cycles) with docetaxel/cisplatin would be
1,067,836 Spanish pesetas (Ptas) (€6481; 5741 USD),
1,365,304 or 1,439,369 Ptas (€8205 or €8651; 7340 or
7738 USD) with paclitaxel/cisplatin (3 or 24 hour infusions,
respectively), and 1,417,995 or 1,616,784 Ptas (€8522 or
€9717; 7623 or 8692 USD) (paclitaxel dose of 175 or 225
mg/m2/day, respectively) with paclitaxel/carboplatin.
CONCLUSIONS: According to our study, the treatment
option docetaxel/cisplatin, with equal efficacy, would re-
sult in a cost saving of between 297,468 and 548,948
Ptas (1788 and 3299 € or 1599 and 2951 USD) per pa-
tient treated. This difference is mainly due to the lower
treatment cost associated with docetaxel.
PCN14
CHEMOTHERAPY-INDUCED NEUROPATHY IN 
OVARIAN CANCER COST 
EFFECTIVENESS ANALYSIS
Hay JW, Patel BV
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: Many widely used chemotherapy agents,
including paclitaxel and cisplatin produce neuropathy in
cancer patients. These symptoms are dose-related, some-
times irreversible, and can lead to treatment withdrawal.
To evaluate reported chemotherapy cost-effectiveness, we
assessed the literature on cost and quality of life burden
of chemotherapy-induced neuropathy in ovarian cancer
(OC) patients.
METHODS: MEDLINE was searched for all articles
published in English between 1966 and June 2001 match-
ing neuropathy or cancer with keywords: quality of life;
burden of disease; cost; cost-effectiveness; cost of illness;
indirect cost. Findings from all relevant international stud-
ies were combined to assess neuropathy cost and utility
burden.
RESULTS: Eight hundred eighty four relevant study refer-
ences were identified and reviewed. Only two studies sys-
tematically evaluated the utility loss associated with severe
neuropathy, and only one study reported indirect cost bur-
den of OC neuropathy. No single analysis provided a com-
prehensive assessment of chemotherapy-induced neuropathy
on treatment cost-effectiveness. Clinical evidence suggests
that the burden is substantial. Up to 57% of cisplatin pa-
tients, and 62% of paclitaxel patients experienced significant
neuropathy symptoms. Quality of life decreased by 17–24%
for OC patients experiencing severe neuropathy. Using 2001
US prices and including the indirect costs and quality of life
impacts, the effect of severe neuropathy would be to increase
typically reported base case cost-effectiveness of pacli-
taxel in OC treatment from $33,300/QALY to $52,800/
QALY. Similar results were found for other oncology medi-
cations.
CONCLUSIONS: Neuropathy quality of life and cost
burden has been ignored in the chemotherapy cost-effec-
tiveness literature, because direct treatment costs are
small and quality of life impacts due to neuropathy in
OC patients are rarely explicitly measured. Nevertheless,
this treatment toxicity may have a substantial effect on
chemotherapy cost-effectiveness, possibly increasing re-
ported medication cost/QALY estimates by 60%. More
research is needed to quantify the cost and quality of life
burdens of chemotherapy-induced neuropathy.
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OBJECTIVES: To assesses the quality of life (QoL) with
Q-TwiST retrospectively in a randomised phase III trial
